European Journal of Haematology

Papers
(The H4-Index of European Journal of Haematology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect133
68
64
Issue Information63
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway60
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy45
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes42
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma40
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates34
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia33
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation30
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg29
Pubertal Assessment and Growth in Patients With Hemoglobinopathies: A Longitudinal Multicenter Study on the Association With Ferritin Levels27
Issue Information27
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial26
Efficacy and Tolerance of Cladribine for Non‐Langerhans Cell Histiocytosis25
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States25
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes24
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review23
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study22
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma20
Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization20
Long‐term effectiveness of eculizumab: Data from the International PNH Registry20
Bridging Trials and Real Life in Fixed‐Duration BTKi –Venetoclax for CLL : A Delphi‐Enhanced Synth20
Issue Information20
Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged ≥ 80 Years20
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea20
0.11616396903992